Activin and inhibin research has provided important insight into reproductive physiology as well as many areas involving regulation of cell growth, differentiation and function. Progress in understanding the roles of these hormones in various cell and tissue types has been complimented by novel discoveries at the molecular level that have shed light on ligand/receptor interactions, signaling mechanisms and regulation. While the receptors and signaling pathway for activin are now well characterized, the molecular basis for inhibin action has remained relatively unclear. Here we summarize recent advances in understanding inhibin's mode of action focusing on our recent identification of betaglycan as an inhibin co-receptor capable of mediating inhibin action.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0303-7207(02)00037-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comprehensive analysis of inhibin-β A as a potential biomarker for gastrointestinal tract cancers through bioinformatics approaches.
Sci Rep
January 2025
Department of Life Sciences, School of Natural Sciences (SONS), Shiv Nadar Institution of Eminence, Delhi NCR, India.
Inhibin, β, which is also known as INHBA, encodes a protein that belongs to the Transforming Growth factor-β (TGF-β) superfamily, which plays a pivotal role in cancer. Gastrointestinal tract (GI tract) cancer refers to the cancers that develop in the colon, liver, esophagus, stomach, rectum, pancreas, and bile ducts of the digestive system. The role of INHBA in all GI tract cancers remains understudied.
View Article and Find Full Text PDFIdentification and Validation of Serum Biomarkers to Improve Colorectal Cancer Diagnosis.
Cancer Med
December 2024
Department of Pathology, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Article Synopsis
- The study addresses the urgent need for reliable biomarkers in colorectal cancer (CRC) diagnosis, highlighting limitations in current methods and the potential for novel, non-invasive solutions.
- Using advanced genomic and proteomic technologies, researchers identified five promising biomarkers: INHBA, MMP7, PSAT1, SLC7A5, and TGFBI, which showed significantly higher expression levels in CRC patients compared to healthy controls.
- The biomarkers demonstrated strong diagnostic accuracy, with AUC values between 0.8361 and 0.9869, suggesting they could greatly improve early detection and precision in CRC diagnostic practices.
Activins and Inhibins in Cardiovascular Pathophysiology.
Biomolecules
November 2024
Department of Cardiology, The First Hospital of China Medical University, Shenyang 110001, China.
Activins and inhibins, members of the transforming growth factor β (TGFβ) superfamily, were initially recognized for their opposing effects on the secretion of follicle-stimulating hormone. Subsequent research has demonstrated their broader biological roles across various tissue types. Primarily, activins and inhibins function through the classical TGFβ SMAD signaling pathway, but studies suggest that they also act through other pathways, with their specific signaling being complex and context-dependent.
View Article and Find Full Text PDFDNA hypomethylation of INHBA promotes tumor progression and predicts prognosis and immune status of gastric cancer.
Hereditas
November 2024
Department of Gastroenterology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310003, China.
Objective: Gastric cancer (GC) is characterized by its high malignancy and poor prognosis. However, the role of Inhibin subunit beta A (INHBA) in GC remains insufficiently understood. This study aims to comprehensively evaluate the clinical significance, biological roles, and possible mechanisms of INHBA in GC.
View Article and Find Full Text PDFThe impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation.
Metabolism
December 2024
Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA; Section of Endocrinology, Boston VA Healthcare System, Harvard Medical School, Boston, MA, USA. Electronic address:
Similar to bariatric surgery, incretin receptor agonists have revolutionized the treatment of obesity, achieving up to 15-25 % weight loss in many patients, i.e., at a rate approaching that achieved with bariatric surgery.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!